Authors: N K Dutta K Mazumdar M W Baek D J Kim Y R Na S H Park H K Lee B H Lee J H Park
Publish Date: 2008/01/09
Volume: 27, Issue: 4, Pages: 315-319
Abstract
Chemotherapy is often futile in systemic listeriosis translating to being a peril to public health There is thus an imperative need for novel antilisterial compounds possibly acting through mechanisms dissimilar to those of existing drugs The present study describes one such agent—the nonsteroidal antiinflammatory drug NSAID diclofenac sodium Dc The National Committee for Clinical Laboratory Standards NCCLS minimum inhibitory concentration MIC mode of action and two mechanisms of action ie on bacterial DNA and membrane have been characterized with respect to Dc The drug showed noteworthy inhibitory action MIC90 = 50 μg/ml against Listeria strains demonstrated cidal minimum bactericidal concentration MBC=100 μg/ml activity inhibited listerial DNA synthesis 4548 incorporation of methyl3H thymidine and possessed bacterial membranedamaging activity 3733 BacLight assay Dc could be used as a lead compound for the synthesis of new more active agents perhaps devoid of side effects Further quantitative structure–activity relationship QSAR studies will contribute to a new generation of promising adjuvants to existing antilisterial drugs
Keywords: